Total: $104 million

Restasis: $43.6 million
Botox (wrinkles): $24 million
Latisse: $9.8 million
Watch the Restasis TV commercial here >>

Allergan ($AGN) made its name with antiwrinkle drug Botox, which it continues to push to consumers. For this time period, it put twice the advertising bucks behind Restasis, a drug for chronic dry eye, as it did for Botox. The patent for it expires in May 2014, the company says, and in June the FDA said it was not going to require generics makers to do clinical trials to get approvals of their copycats. That news was a gut blow to Allergan. As well as advertising it heavily, the company has been notching up the price of the drug in 5% increments for some time. It says all of the rebates and discounts make it impossible to know what the net effect of those price hikes are, but it did report a 10.8% sales jump for the 6 months, hitting $423.1 million.


Suggested Articles

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.